tiprankstipranks
Trending News
More News >
BioLife Solutions Inc (BLFS)
:BLFS
US Market
Advertisement

BioLife Solutions (BLFS) Stock Forecast & Price Target

Compare
408 Followers
See the Price Targets and Ratings of:

BLFS Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
BioLife
Solutions
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BLFS Stock 12 Month Forecast

Average Price Target

$31.22
▲(13.86% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for BioLife Solutions in the last 3 months. The average price target is $31.22 with a high forecast of $34.00 and a low forecast of $30.00. The average price target represents a 13.86% change from the last price of $27.42.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","23":"$23","27":"$27","31":"$31","35":"$35"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,23,27,31,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.13,26.735384615384614,27.34076923076923,27.946153846153845,28.55153846153846,29.156923076923075,29.76230769230769,30.36769230769231,30.973076923076924,31.57846153846154,32.183846153846154,32.78923076923077,33.394615384615385,{"y":34,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.13,26.521538461538462,26.913076923076922,27.304615384615385,27.696153846153845,28.087692307692308,28.479230769230767,28.87076923076923,29.26230769230769,29.653846153846153,30.045384615384613,30.436923076923076,30.82846153846154,{"y":31.22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.13,26.427692307692308,26.725384615384616,27.02307692307692,27.32076923076923,27.61846153846154,27.916153846153847,28.213846153846152,28.51153846153846,28.80923076923077,29.106923076923078,29.404615384615383,29.70230769230769,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.14,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.07,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.27,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.96,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.83,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.6,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.66,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.13,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$34.00Average Price Target$31.22Lowest Price Target$30.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen
$26.8$31
Buy
13.06%
Upside
Reiterated
10/13/25
TD Cowen Sticks to Its Buy Rating for BioLife Solutions (BLFS)
Northland Securities Analyst forecast on BLFS
Northland Securities
Northland Securities
$31
Buy
13.06%
Upside
Reiterated
10/08/25
BioLife Solutions (BLFS) Gets a Buy from Northland Securities
Jefferies Analyst forecast on BLFS
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$30
Buy
9.41%
Upside
Reiterated
10/08/25
BioLife Solutions (BLFS) Receives a Buy from Jefferies
Lake Street Analyst forecast on BLFS
Lake Street
Lake Street
$30
Buy
9.41%
Upside
Reiterated
10/07/25
Analysts Offer Insights on Healthcare Companies: ClearPoint Neuro (NASDAQ: CLPT), BioLife Solutions (NASDAQ: BLFS) and Viking Therapeutics (NASDAQ: VKTX)
KeyBanc
$33
Buy
20.35%
Upside
Reiterated
10/03/25
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (NASDAQ: BLFS), Pacific Biosciences (NASDAQ: PACB) and Humana (NYSE: HUM)
Craig-Hallum Analyst forecast on BLFS
Craig-Hallum
Craig-Hallum
Buy
Reiterated
10/01/25
Analysts' Top Healthcare Picks: BioLife Solutions (BLFS), Dexcom (DXCM)
TR | OpenAI - 4o Analyst forecast on BLFS
TR | OpenAI - 4o
TR | OpenAI - 4o
$24.5$25
Hold
-8.83%
Downside
Reiterated
09/27/25
AI Generated ArticleAI Generated Article
Maxim Group Analyst forecast on BLFS
Maxim Group
Maxim Group
$34
Buy
24.00%
Upside
Reiterated
08/12/25
BioLife Solutions: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating
Benchmark Co. Analyst forecast on BLFS
Benchmark Co.
Benchmark Co.
$30
Buy
9.41%
Upside
Reiterated
08/11/25
Analysts Conflicted on These Healthcare Names: Green Thumb Industries (Other OTC: GTBIF), Doximity (NYSE: DOCS) and BioLife Solutions (NASDAQ: BLFS)We are maintaining our Buy rating and $30 price target on BLFS shares on the solid 2Q25 results.
H.C. Wainwright Analyst forecast on BLFS
H.C. Wainwright
H.C. Wainwright
$30$32
Buy
16.70%
Upside
Reiterated
08/08/25
BioLife Solutions price target raised to $32 from $30 at H.C. WainwrightBioLife Solutions price target raised to $32 from $30 at H.C. Wainwright
Stephens Analyst forecast on BLFS
Stephens
Stephens
$30
Buy
9.41%
Upside
Initiated
07/21/25
BioLife Solutions resumed with an Overweight at StephensBioLife Solutions resumed with an Overweight at Stephens
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen
$26.8$31
Buy
13.06%
Upside
Reiterated
10/13/25
TD Cowen Sticks to Its Buy Rating for BioLife Solutions (BLFS)
Northland Securities Analyst forecast on BLFS
Northland Securities
Northland Securities
$31
Buy
13.06%
Upside
Reiterated
10/08/25
BioLife Solutions (BLFS) Gets a Buy from Northland Securities
Jefferies Analyst forecast on BLFS
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$30
Buy
9.41%
Upside
Reiterated
10/08/25
BioLife Solutions (BLFS) Receives a Buy from Jefferies
Lake Street Analyst forecast on BLFS
Lake Street
Lake Street
$30
Buy
9.41%
Upside
Reiterated
10/07/25
Analysts Offer Insights on Healthcare Companies: ClearPoint Neuro (NASDAQ: CLPT), BioLife Solutions (NASDAQ: BLFS) and Viking Therapeutics (NASDAQ: VKTX)
KeyBanc
$33
Buy
20.35%
Upside
Reiterated
10/03/25
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (NASDAQ: BLFS), Pacific Biosciences (NASDAQ: PACB) and Humana (NYSE: HUM)
Craig-Hallum Analyst forecast on BLFS
Craig-Hallum
Craig-Hallum
Buy
Reiterated
10/01/25
Analysts' Top Healthcare Picks: BioLife Solutions (BLFS), Dexcom (DXCM)
TR | OpenAI - 4o Analyst forecast on BLFS
TR | OpenAI - 4o
TR | OpenAI - 4o
$24.5$25
Hold
-8.83%
Downside
Reiterated
09/27/25
AI Generated ArticleAI Generated Article
Maxim Group Analyst forecast on BLFS
Maxim Group
Maxim Group
$34
Buy
24.00%
Upside
Reiterated
08/12/25
BioLife Solutions: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating
Benchmark Co. Analyst forecast on BLFS
Benchmark Co.
Benchmark Co.
$30
Buy
9.41%
Upside
Reiterated
08/11/25
Analysts Conflicted on These Healthcare Names: Green Thumb Industries (Other OTC: GTBIF), Doximity (NYSE: DOCS) and BioLife Solutions (NASDAQ: BLFS)We are maintaining our Buy rating and $30 price target on BLFS shares on the solid 2Q25 results.
H.C. Wainwright Analyst forecast on BLFS
H.C. Wainwright
H.C. Wainwright
$30$32
Buy
16.70%
Upside
Reiterated
08/08/25
BioLife Solutions price target raised to $32 from $30 at H.C. WainwrightBioLife Solutions price target raised to $32 from $30 at H.C. Wainwright
Stephens Analyst forecast on BLFS
Stephens
Stephens
$30
Buy
9.41%
Upside
Initiated
07/21/25
BioLife Solutions resumed with an Overweight at StephensBioLife Solutions resumed with an Overweight at Stephens
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioLife Solutions

1 Month
xxx
Success Rate
11/16 ratings generated profit
69%
Average Return
+4.96%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 68.75% of your transactions generating a profit, with an average return of +4.96% per trade.
3 Months
xxx
Success Rate
21/28 ratings generated profit
75%
Average Return
+23.86%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +23.86% per trade.
1 Year
Matt HewittCraig-Hallum
Success Rate
15/16 ratings generated profit
94%
Average Return
+32.01%
reiterated a buy rating 14 days ago
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 93.75% of your transactions generating a profit, with an average return of +32.01% per trade.
2 Years
xxx
Success Rate
16/16 ratings generated profit
100%
Average Return
+37.37%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +37.37% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BLFS Analyst Recommendation Trends

Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
0
0
0
0
0
Buy
9
11
12
11
13
Hold
8
9
8
9
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
20
20
20
17
In the current month, BLFS has received 13 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. BLFS average Analyst price target in the past 3 months is 31.22.
Each month's total comprises the sum of three months' worth of ratings.

BLFS Financial Forecast

BLFS Earnings Forecast

Next quarter’s earnings estimate for BLFS is -$0.01 with a range of -$0.02 to $0.01. The previous quarter’s EPS was -$0.33. BLFS beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year BLFS has Preformed in-line its overall industry.
Next quarter’s earnings estimate for BLFS is -$0.01 with a range of -$0.02 to $0.01. The previous quarter’s EPS was -$0.33. BLFS beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year BLFS has Preformed in-line its overall industry.

BLFS Sales Forecast

Next quarter’s sales forecast for BLFS is $25.69M with a range of $25.09M to $26.00M. The previous quarter’s sales results were $25.42M. BLFS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year BLFS has Preformed in-line its overall industry.
Next quarter’s sales forecast for BLFS is $25.69M with a range of $25.09M to $26.00M. The previous quarter’s sales results were $25.42M. BLFS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year BLFS has Preformed in-line its overall industry.

BLFS Stock Forecast FAQ

What is BLFS’s average 12-month price target, according to analysts?
Based on analyst ratings, BioLife Solutions Inc’s 12-month average price target is 31.22.
    What is BLFS’s upside potential, based on the analysts’ average price target?
    BioLife Solutions Inc has 13.86% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BLFS a Buy, Sell or Hold?
          BioLife Solutions Inc has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is BioLife Solutions Inc’s price target?
            The average price target for BioLife Solutions Inc is 31.22. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $34.00 ,the lowest forecast is $30.00. The average price target represents 13.86% Increase from the current price of $27.42.
              What do analysts say about BioLife Solutions Inc?
              BioLife Solutions Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of BLFS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis